Summary
Amgen Inc. (AMGN) has officially announced the completion of its acquisition of ChemoCentryx, Inc. as of October 19, 2022. This strategic move, detailed in a press release filed on October 20, 2022, signifies a significant expansion of Amgen's capabilities, particularly in the area of inflammatory and autoimmune diseases, which was a key focus for ChemoCentryx. Investors should note that this acquisition is expected to bolster Amgen's pipeline and market presence in these therapeutic areas.
Key Highlights
- 1Amgen Inc. has successfully completed the acquisition of ChemoCentryx, Inc.
- 2The acquisition was completed on October 19, 2022.
- 3This event was officially disclosed via a press release filed as an 8-K on October 20, 2022.
- 4The transaction is expected to enhance Amgen's portfolio, particularly in inflammatory and autoimmune disease treatments.
- 5ChemoCentryx was known for its focus on orally administered therapeutics for autoimmune and inflammatory diseases.
- 6The press release attached as Exhibit 99.1 provides further details on the acquisition.